中药市场应慎用“降价令”——基于统计资料的分析  

Prudent use price controls in Chinese medicines market:based on statistical data analysis

作　　者：杨光[1,2] 王诺[3] 黄璐琦[2] 邱红燕[4] 郭兰萍[2] 

机构地区：[1]北京师范大学资源学院,北京100875 [2]中国中医科学院中药资源中心,北京100700 [3]北京师范大学经济与资源管理研究院,北京1000875 [4]宁夏医科大学,宁夏银川750004

出　　处：《中国中药杂志》2014年第1期144-148,共5页China Journal of Chinese Materia Medica

基　　金：国家自然科学基金项目(81130070;81072989);国家科技支撑计划项目(2012BAI29B02;2012BAI28B002)

摘　　要：中成药是否应该降价常引起争议。通过分析1995—2011年统计数据,结果发现:看病贵的主要责任并不在药品价格增长;对中药而言其价格指数上涨明显慢于药材价格上涨,1995年至今我国中成药生产的利润率受原料价格影响处于下降状态,如果再下调中成药价格对行业无疑是雪上加霜;中成药的成本有高有低,优劣原料价格平均相差1倍,如果再进行降价将把中成药逼向假劣药横行的状况。A dispute about the decreasing-price problem of traditional Chinese medicine （TCM） has recently arisen. This arti- cle analyzes the statistical data of 1995--2011 in China, the results showed that the main responsibility of expensive health care has no direct relationship with the drug price. The price index of TCM rose significantly slower than the medicine prices, the production margins of TCM affected by the material prices has been diminishing since 1995, continuous price reduction will further depress profits of the TCM industry. Considering the pros and cons of raw materials vary greatly in price, decreasing medicine price behavior will force enterprises to use inferior materials in order to maintain corporate profits. The results have the guiding meaning to medicine price management.

关 键 词：中成药 降价令 中药质量 人均药品费用 价格指数 

分 类 号：F426.72[经济管理—产业经济]